Mitoepigenetics pathways and natural compounds: a dual approach to combatting hepatocellular carcinoma.

IF 2.8 4区医学 Q2 ONCOLOGY

Medical Oncology Pub Date : 2024-10-27 DOI:10.1007/s12032-024-02538-8

Abdulrahman Hatawsh, Roya Hadi Al-Haddad, Ukamaka Gladys Okafor, Lamis M Diab, Nino Dekanoidze, Adeniyi Ayinde Abdulwahab, Osama A Mohammed, Ahmed S Doghish, Rewan Moussa, Hanan Elimam

{"title":"Mitoepigenetics pathways and natural compounds: a dual approach to combatting hepatocellular carcinoma.","authors":"Abdulrahman Hatawsh, Roya Hadi Al-Haddad, Ukamaka Gladys Okafor, Lamis M Diab, Nino Dekanoidze, Adeniyi Ayinde Abdulwahab, Osama A Mohammed, Ahmed S Doghish, Rewan Moussa, Hanan Elimam","doi":"10.1007/s12032-024-02538-8","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC) is a leading liver cancer that significantly impacts global life expectancy and remains challenging to treat due to often late diagnoses. Despite advances in treatment, the prognosis is still poor, especially in advanced stages. Studies have pointed out that investigations into the molecular mechanisms underlying HCC, including mitochondrial dysfunction and epigenetic regulators, are potentially important targets for diagnosis and therapy. Mitoepigenetics, or the epigenetic modifications of mitochondrial DNA, have drawn wide attention for their role in HCC progression. Besides, molecular biomarkers such as mitochondrial DNA alterations and non-coding RNAs showed early diagnosis and prognosis potential. Additionally, natural compounds like alkaloids, resveratrol, curcumin, and flavonoids show promise in HCC show promise in modulating mitochondrial and epigenetic pathways involved in cancer-related processes. This review discusses how mitochondrial dysfunction and epigenetic modifications, especially mitoepigenetics, influence HCC and delves into the potential of natural products as new adjuvant treatments against HCC.</p>","PeriodicalId":18433,"journal":{"name":"Medical Oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12032-024-02538-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Hepatocellular carcinoma (HCC) is a leading liver cancer that significantly impacts global life expectancy and remains challenging to treat due to often late diagnoses. Despite advances in treatment, the prognosis is still poor, especially in advanced stages. Studies have pointed out that investigations into the molecular mechanisms underlying HCC, including mitochondrial dysfunction and epigenetic regulators, are potentially important targets for diagnosis and therapy. Mitoepigenetics, or the epigenetic modifications of mitochondrial DNA, have drawn wide attention for their role in HCC progression. Besides, molecular biomarkers such as mitochondrial DNA alterations and non-coding RNAs showed early diagnosis and prognosis potential. Additionally, natural compounds like alkaloids, resveratrol, curcumin, and flavonoids show promise in HCC show promise in modulating mitochondrial and epigenetic pathways involved in cancer-related processes. This review discusses how mitochondrial dysfunction and epigenetic modifications, especially mitoepigenetics, influence HCC and delves into the potential of natural products as new adjuvant treatments against HCC.

查看原文本刊更多论文

线粒体表观遗传学途径和天然化合物：抗击肝细胞癌的双重方法。

肝细胞癌（HCC）是一种严重影响全球预期寿命的主要肝癌，由于往往诊断较晚，治疗难度仍然很大。尽管治疗手段不断进步，但预后仍然很差，尤其是晚期患者。研究指出，研究 HCC 的分子机制（包括线粒体功能障碍和表观遗传调节因子）可能是诊断和治疗的重要目标。线粒体表观遗传学或线粒体 DNA 的表观遗传修饰在 HCC 进展中的作用已引起广泛关注。此外，线粒体 DNA 改变和非编码 RNA 等分子生物标志物也显示出早期诊断和预后的潜力。此外，生物碱、白藜芦醇、姜黄素和黄酮类化合物等天然化合物在调节参与癌症相关过程的线粒体和表观遗传途径方面也大有可为。这篇综述讨论了线粒体功能障碍和表观遗传修饰（尤其是线粒体表观遗传学）如何影响 HCC，并深入探讨了天然产品作为 HCC 新辅助疗法的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Oncology 医学-肿瘤学

CiteScore

4.20

自引率

2.90%

发文量

259

审稿时长

1.4 months

期刊介绍： Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.